LYTIR

Company · ENGN

enGene Therapeutics Inc.

Nasdaq's symbol directory lists ENGN on Nasdaq as “enGene Therapeutics Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 1 occasion ($10K); 5 filings by holders of 5% or more.

All insider filings at the SEC

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. William Grossman, Interim Chief Medical Officer bought on 1 day latest Sep 22, 2026 bought $10K
Every trade (1)
  1. BUYWilliam Grossman, Interim Chief Medical Officer bought Sep 22, 2026 5,102 shares filing $10K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Perceptive Advisors LLC filed Aug 14, 2026 Schedule 13G/A passive filing 9.99%
  2. Venrock Healthcare Capital Partners III, L.P. filed Aug 14, 2026 Schedule 13G/A passive filing 0%
  3. Deep Track Capital, LP filed Aug 14, 2026 Schedule 13G/A passive 0 shares filing 0%
  4. Invus Global Management, LLC filed Aug 13, 2026 Schedule 13G/A passive filing 8.2%
  5. Blue Owl Capital Holdings LP filed Aug 12, 2026 Schedule 13G/A passive filing 0.76%

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.